Krakow, Poland – 15 February 2019 – Selvita, one of the largest drug discovery companies in Europe, announced that Selvita Analytical Laboratory GMP Certifications will be automatically recognized by the FDA from February 7, 2019. Thanks to the mutual recognition agreement between the Food and Drug Administration and the…
Selvita to Present at Biotech Showcase 2019 in San Francisco
Krakow, Poland – 2 January 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that Chief Executive Officer Pawel Przewiezlikowski will present a corporate overview at the Biotech Showcase 2019 conference taking place Jan. 7-9…
Selvita Announces Presentations on CDK8 Inhibitor SEL120 at the 60th American Society of Hematology Annual Meeting
Krakow, Poland – 21 November 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced that preclinical data from SEL120, a CDK8 inhibitor in development for the treatment of acute myeloid leukemia, has been accepted for…
Selvita demonstrates dynamic business growth in Q3 2018
Krakow, Poland – 20 November 2018 – Selvita (WSE: SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, has recently published quarterly financial results demonstrating its continued dynamic business growth. In Q3 2018 Selvita Group recognized total commercial revenue (not…
Selvita to Present New Data from SEL120 Program at EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Krakow, Poland – 8 November 2018 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, will present a new data from SEL120 program at the 30th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. The conference is taking place…
Selvita presents at BIO-Europe 2018
Kraków, Poland – 2 November 2018 – Selvita (WSE: SLV), a clinical stage drug discovery and development company focused on innovative medicines for oncology patients and drug discovery services, will participate and present at the BIO-Europe 2018 conference, which is taking place on November 5-7, 2018, in Copenhagen, Denmark. The…